Avadel Pharmaceuticals’ Lumryz™ (sodium oxybate) has been tentatively approved to treat cataplexy and excessive daytime sleepiness (EDS) caused by narcolepsy.

• Lumryz is a once-nightly formulation of sodium oxybate, whereas the currently available sodium oxybate formulations, Xyrem and Xywav, are taken twice nightly, requiring middle-of-the-night dosing.
• Launch and pricing information are not yet Avadel noted that Lumryz could be granted final approval on or before June 2023.